Talaris Therapeutics, Inc. Announces Promising Phase 2 Data of Novel, Allogenic Cell Therapy in Living Donor Kidney Transplant Recipients by mparnell | Apr 18, 2019 | Portfolio News
Robust Analgesic Activity of Aptinyx’s NYX-2925 in Advanced DPN Patients Revealed Through Further Analysis of Data from Phase 2 Study by mparnell | Apr 18, 2019 | Portfolio News
Poseida Therapeutics Announces Notice of Allowance for New Patents and Registration of New Trademarks by mparnell | Apr 13, 2019 | Portfolio News
Vifor Pharma and Akebia Therapeutics Announce Expansion of License Agreement by mparnell | Apr 9, 2019 | Portfolio News
Nabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) by mparnell | Apr 1, 2019 | Portfolio News